These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Zhou Q; Liao JK Curr Pharm Des; 2009; 15(5):467-78. PubMed ID: 19199975 [TBL] [Abstract][Full Text] [Related]
8. The HMG-CoA reductase pathway, statins and angioprevention. Feng C; Han A; Ye C; Xu R; Li M Semin Ophthalmol; 2006; 21(1):29-35. PubMed ID: 16517442 [TBL] [Abstract][Full Text] [Related]
9. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering. Pedersen TR Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729 [TBL] [Abstract][Full Text] [Related]
10. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction? Comparato C; Altana C; Bellosta S; Baetta R; Paoletti R; Corsini A Nutr Metab Cardiovasc Dis; 2001 Oct; 11(5):328-43. PubMed ID: 11887430 [TBL] [Abstract][Full Text] [Related]
12. Statin therapy in cardiovascular diseases other than atherosclerosis. Beaudry D; Stone KE; Wetherold S; Hemphill J; Do D; McClish J; Chilton R Curr Atheroscler Rep; 2007 Jan; 9(1):25-32. PubMed ID: 17228487 [TBL] [Abstract][Full Text] [Related]
13. Pleiotropic Benefits of Statins in Cardiovascular Diseases. Wasim R; Ansari TM; Ahsan F; Siddiqui MH; Singh A; Shariq M; Parveen S Drug Res (Stuttg); 2022 Nov; 72(9):477-486. PubMed ID: 35868336 [TBL] [Abstract][Full Text] [Related]
14. Pleiotropic effects of statins: A focus on cancer. Ahmadi M; Amiri S; Pecic S; Machaj F; Rosik J; Łos MJ; Alizadeh J; Mahdian R; da Silva Rosa SC; Schaafsma D; Shojaei S; Madrakian T; Zeki AA; Ghavami S Biochim Biophys Acta Mol Basis Dis; 2020 Dec; 1866(12):165968. PubMed ID: 32927022 [TBL] [Abstract][Full Text] [Related]
15. Effect of statins on toll-like receptors: a new insight to pleiotropic effects. Bahrami A; Parsamanesh N; Atkin SL; Banach M; Sahebkar A Pharmacol Res; 2018 Sep; 135():230-238. PubMed ID: 30120976 [TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Lennernäs H; Fager G Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173 [TBL] [Abstract][Full Text] [Related]
18. Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. Yeganeh B; Wiechec E; Ande SR; Sharma P; Moghadam AR; Post M; Freed DH; Hashemi M; Shojaei S; Zeki AA; Ghavami S Pharmacol Ther; 2014 Jul; 143(1):87-110. PubMed ID: 24582968 [TBL] [Abstract][Full Text] [Related]
19. Effects of statin therapy on the progression of chronic kidney disease. Shah S; Paparello J; Danesh FR Adv Chronic Kidney Dis; 2005 Apr; 12(2):187-95. PubMed ID: 15822054 [TBL] [Abstract][Full Text] [Related]
20. Statins: potential new indications in inflammatory conditions. Endres M Atheroscler Suppl; 2006 Apr; 7(1):31-5. PubMed ID: 16503422 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]